between 2010 and 2017. Cases who had undergone invasive testing or NIPT prior to the diagnosis of the CNS anomaly were excluded. Cases were segregated according to whether they were seen prior to introduction of NIPT (Group A, 2010 (Group A, -2013 or thereafter (Group B, 2014 (Group B, -2017 . We examined the rate of invasive and non-invasive genetic testing in each group. RESULTS: We retrieved 500 cases of fetal CNS anomalies (Fig1). Overall, 308 (62%) cases were isolated and 192 (38%) had additional structural anomalies ('complex'). In the total cohort, 165 women (33%) underwent expectant management with no further prenatal genetic testing, 166 (33%) had invasive testing, 52 (10%) had NIPT and 117 pregnancies (23%) were terminated without further genetic tests. In Group B, 21% underwent NIPT. The introduction of NIPT significantly decreased the number of pregnancies having no genetic testing (44% Group A vs 22% in group B, p<0.0001.) but did not change the uptake of invasive testing (34% vs 32% in group A and B, respectively; p¼0.61).
In subgroup analysis, this decrease in patients choosing no testing was only significant in the subgroup of patients presenting with ventriculomegaly: where in group A 43 of 60 cases of fetal ventriculomegaly (72%) chose not to have any further testing, only 22 of 60 (37%) in group B chose not to have further testing in group B (p ¼0.0002).
Of 47 low-risk NIPTs, 17 had follow-up with microarray, 3 of which showed pathogenic copy number variants (18%) ( Table 1) . CONCLUSION: Uptake of invasive prenatal testing in fetuses with brain anomalies was not affected by the introduction of NIPT. NIPT missed a significant number of CNVs.
920 Microsoft Excel-based decision analysis to determine the cost effectiveness of fetal aneuploidy screening OBJECTIVE: Decision analysis is a powerful tool in determining the cost effectiveness of medical interventions. However, such analyses require access to expensive and unintuitive software. As a proof of concept, we attempt to use Microsoft Excel-a more widely used program-to analyze the cost effectiveness of aneuploidy screenings. STUDY DESIGN: Though both sequential screening and cell free DNA (cfDNA) testing are widely offered in the clinic, various professional organizations disagree on which method is better suited for younger, low-risk populations. This issue is further complicated by inconsistent insurance coverage for cfDNA tests and low-risk patients' willingness to pay out-of-pocket. Thus, we designed an Excel algorithm that outputs the most cost-effective aneuploidy screening based on the patient's age and out-of-pocket costs for both types of screenings. The algorithm is fed up-to-date risks for common trisomy disorders (13, 18, 21), screening sensitivities, costs of diagnostic tests (CVS or amniocentesis), procedure related pregnancy loss in case of false positives, and the possibility of missing aneuploidy (Table 1) . The program was simplified with macro functions that quickly recalculate costs after changing one or more inputs. RESULTS: The program successfully calculates the three most costeffective combinations of screenings/diagnostics based on the patient's age and ability to pay. In addition, the algorithm calculates the exact price point at which an initial cfDNA test becomes more cost effective than a sequential screening from ages 19-44 (Table 2) . In other words, a patient could easily determine the maximum price of a cfDNA test at which it would be more cost-effective for the patient to pay for the test herself, rather than undergoing sequential screening. CONCLUSION: Microsoft Excel can be used to carry out complex decision analysis and be useful in helping patients and physicians plan the most cost-effective screening/diagnostic regiment. Up-to-date risks statistics and more accurate assumptions on costs can further improve this algorithm, while such inexpensive and more intuitive Excel-based algorithms can be applied to other clinical settings beyond aneuploidy screening.
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OBJECTIVE:
The placenta is at the core of many pregnancy pathologies, but we have limited knowledge about placental function because of two key research barriers: 1) until recently, there were no consensus guidelines for sample collection and pathologic diagnosis; and 2) limited tools are available to conduct molecular analysis of stored placental samples. We aimed to create a searchable and extensive population-based placental database of pathologic diagnoses and to validate molecular methods to allow for future gene expression studies on formalin fixed paraffin embedded (FFPE) placental blocks. STUDY DESIGN: We used a single university-based hospital's collection of placental FFPE blocks and matched electronic medical records. Placentas from all deliveries, regardless of clinical indication, were assessed and stored from 2012-2017, providing an unbiased cohort of placental samples. We built an IRB-approved Research Electronic Data Capture (REDCap) database and included: maternal pre, peri and post-partum conditions, fetal outcome, macroscopic and microscopic placental findings. This database can be easily
